bioMérieux S.A. (BIM.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BIM.PA in your mock portfolio yet.
With a PE ratio of 20.28 and EPS of 3.34, bioMérieux S.A. appears reasonably valued for a profitable, established diagnostics company, but not clearly cheap given its recent share-price weakness. The valuation implies the market still expects steady earnings, yet the recent drawdown suggests concerns about growth durability or margin pressure. In the absence of detailed revenue and margin trends, the financial picture looks solid but not compellingly strong.
The stock is trading at €67.75, down 8.1% over the last month and far below its 200‑day moving average of €97.70, indicating a pronounced downtrend. This wide gap to the 200‑day average is a strong technical sign of sustained selling pressure and weak momentum. Absent evidence of capitulation or a clear reversal pattern, the technical setup leans clearly negative in the near term.
Alternative data for bioMérieux S.A. show a broadly stable to slightly improving operational and brand footprint, with modest growth in social channels and a small uptick in job openings. Web traffic and app downloads appear healthy in absolute terms, supporting ongoing customer engagement, though we lack prior-period benchmarks to confirm strong growth. Overall, these signals are not weak, but they are not strong enough to offset the clearly negative technical picture.
Despite a reasonable earnings profile and stable alternative data signals, the stock’s pronounced break below its 200‑day moving average and recent 8.1% monthly decline tilt the overall view to bearish in the near term. The market appears to be discounting future growth or profitability more aggressively than the current earnings multiple alone would suggest, and there is no clear technical evidence yet of a bottoming process.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started